The future directions is to clarify why immunological checkpoint molecules such as PD-L1 can affect the glycolysis of tumor cells, and further explore the value of 18F-FDG PET/CT in predicting anti-PD-1/PD-L1 therapy response, it plays a key role in selecting the best treatment strategy for CRC patients. Here, CD274 is linked to neoplasm.